Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/EIF5_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/EIF5_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/EIF5_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/EIF5_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/EIF5_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EIF5_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/EIF5_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/EIF5_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EIF5_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/EIF5_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/EIF5_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/EIF5_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00510286 | Prostate | BPH | mRNA transport | 35/3107 | 130/18723 | 1.93e-03 | 1.10e-02 | 35 |
GO:00436243 | Prostate | BPH | cellular protein complex disassembly | 34/3107 | 136/18723 | 7.81e-03 | 3.42e-02 | 34 |
GO:00985865 | Prostate | BPH | cellular response to virus | 23/3107 | 84/18723 | 8.59e-03 | 3.68e-02 | 23 |
GO:000218119 | Prostate | Tumor | cytoplasmic translation | 115/3246 | 148/18723 | 1.36e-58 | 8.43e-55 | 115 |
GO:200123319 | Prostate | Tumor | regulation of apoptotic signaling pathway | 137/3246 | 356/18723 | 1.01e-21 | 1.25e-18 | 137 |
GO:000641317 | Prostate | Tumor | translational initiation | 66/3246 | 118/18723 | 2.57e-21 | 2.66e-18 | 66 |
GO:000641719 | Prostate | Tumor | regulation of translation | 161/3246 | 468/18723 | 1.55e-19 | 8.74e-17 | 161 |
GO:002261319 | Prostate | Tumor | ribonucleoprotein complex biogenesis | 159/3246 | 463/18723 | 3.17e-19 | 1.52e-16 | 159 |
GO:009719319 | Prostate | Tumor | intrinsic apoptotic signaling pathway | 113/3246 | 288/18723 | 6.79e-19 | 2.64e-16 | 113 |
GO:007182619 | Prostate | Tumor | ribonucleoprotein complex subunit organization | 91/3246 | 227/18723 | 3.62e-16 | 7.50e-14 | 91 |
GO:002261819 | Prostate | Tumor | ribonucleoprotein complex assembly | 89/3246 | 220/18723 | 3.94e-16 | 7.89e-14 | 89 |
GO:200124219 | Prostate | Tumor | regulation of intrinsic apoptotic signaling pathway | 72/3246 | 164/18723 | 1.63e-15 | 2.81e-13 | 72 |
GO:000644615 | Prostate | Tumor | regulation of translational initiation | 44/3246 | 79/18723 | 1.37e-14 | 1.89e-12 | 44 |
GO:003425018 | Prostate | Tumor | positive regulation of cellular amide metabolic process | 68/3246 | 162/18723 | 1.42e-13 | 1.63e-11 | 68 |
GO:000218317 | Prostate | Tumor | cytoplasmic translational initiation | 25/3246 | 34/18723 | 8.99e-13 | 8.73e-11 | 25 |
GO:004572718 | Prostate | Tumor | positive regulation of translation | 59/3246 | 136/18723 | 1.06e-12 | 9.98e-11 | 59 |
GO:007233119 | Prostate | Tumor | signal transduction by p53 class mediator | 63/3246 | 163/18723 | 7.82e-11 | 4.96e-09 | 63 |
GO:200123517 | Prostate | Tumor | positive regulation of apoptotic signaling pathway | 51/3246 | 126/18723 | 7.27e-10 | 3.59e-08 | 51 |
GO:000640317 | Prostate | Tumor | RNA localization | 70/3246 | 201/18723 | 1.58e-09 | 7.32e-08 | 70 |
GO:000173217 | Prostate | Tumor | formation of cytoplasmic translation initiation complex | 14/3246 | 16/18723 | 1.83e-09 | 8.30e-08 | 14 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EIF5 | SNV | Missense_Mutation | | c.39C>G | p.Phe13Leu | p.F13L | P55010 | protein_coding | deleterious(0.03) | possibly_damaging(0.558) | TCGA-A2-A0YL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
EIF5 | SNV | Missense_Mutation | | c.238C>T | p.His80Tyr | p.H80Y | P55010 | protein_coding | deleterious(0) | benign(0.277) | TCGA-A2-A0YL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
EIF5 | SNV | Missense_Mutation | rs779336285 | c.124G>A | p.Val42Ile | p.V42I | P55010 | protein_coding | tolerated(0.55) | benign(0.013) | TCGA-D8-A1JD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
EIF5 | SNV | Missense_Mutation | | c.33N>G | p.Asp11Glu | p.D11E | P55010 | protein_coding | deleterious(0) | possibly_damaging(0.87) | TCGA-E2-A14O-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | SD |
EIF5 | insertion | In_Frame_Ins | novel | c.321_322insTGTCTTGCAGCTTATTCGCCTCAT | p.Thr107_Asp108insCysLeuAlaAlaTyrSerProHis | p.T107_D108insCLAAYSPH | P55010 | protein_coding | | | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
EIF5 | insertion | Nonsense_Mutation | novel | c.507_508insCGAGGTCAGGAGTTCTAGACCAGCCTAGCCAACAT | p.Asn170ArgfsTer6 | p.N170Rfs*6 | P55010 | protein_coding | | | TCGA-A8-A09W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
EIF5 | insertion | Nonsense_Mutation | novel | c.311_312insCGTCTGATTGCCAAGGTAATAAACTGCTCTTCAATTTAGT | p.Pro105ValfsTer2 | p.P105Vfs*2 | P55010 | protein_coding | | | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
EIF5 | SNV | Missense_Mutation | novel | c.1204N>A | p.Glu402Lys | p.E402K | P55010 | protein_coding | deleterious(0.02) | benign(0.173) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
EIF5 | SNV | Missense_Mutation | novel | c.89N>G | p.Asn30Ser | p.N30S | P55010 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-MA-AA3Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
EIF5 | SNV | Missense_Mutation | novel | c.173N>T | p.Gly58Val | p.G58V | P55010 | protein_coding | deleterious(0) | benign(0.267) | TCGA-VS-A9V5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |